Trials
5 active
6 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide”In the company’s words, NCT06154252 on ClinicalTrials.gov
- Tested for
- Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis and 7 more
- Main trialPhase 2/3
- “RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy”In the company’s words, NCT06154252 on ClinicalTrials.gov
- Other names
- Rese-cel · Resecabtagene autoleucel
Other drugs for Idiopathic Inflammatory Myopathy
- AnifrolumabAstraZeneca · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
- BMS-986353Bristol Myers Squibb · Phase 3
- BelimumabGSK · Phase 3
- NerandomilastBoehringer Ingelheim · Phase 3
- ABBV-722AbbVie · Phase 2/3
Coming up5
- Jul 2028Phase 2/3 trial completes · ClinicalTrials.gov
- Jan 2029Phase 1/2 trial completes · ClinicalTrials.gov
- Jul 2029Phase 2/3 trial completes · ClinicalTrials.gov
- Sep 2029Phase 1/2 trial completes · ClinicalTrials.gov
- Dec 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | Jul 2028 | RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy | |
| Phase 2/3Recruiting | Jul 2029 | RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis | |
| Phase 1/2Recruiting | Jan 2029 | A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) | |
| Phase 1/2Recruiting | Sep 2029 | RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | |
| Phase 1/2Recruiting | Dec 2029 | RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | |
| Phase 1/2Withdrawn | Sep 2028 | RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026